558 related articles for article (PubMed ID: 35046573)
1. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
VanBlargan LA; Errico JM; Halfmann PJ; Zost SJ; Crowe JE; Purcell LA; Kawaoka Y; Corti D; Fremont DH; Diamond MS
Nat Med; 2022 Mar; 28(3):490-495. PubMed ID: 35046573
[TBL] [Abstract][Full Text] [Related]
2. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
VanBlargan L; Errico J; Halfmann P; Zost S; Crowe J; Purcell L; Kawaoka Y; Corti D; Fremont D; Diamond M
Res Sq; 2021 Dec; ():. PubMed ID: 34981042
[TBL] [Abstract][Full Text] [Related]
3. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
Jawad B; Adhikari P; Podgornik R; Ching WY
Comput Biol Med; 2023 Dec; 167():107576. PubMed ID: 37871435
[TBL] [Abstract][Full Text] [Related]
4. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
Zhou H; Dcosta BM; Landau NR; Tada T
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
[TBL] [Abstract][Full Text] [Related]
5. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
[TBL] [Abstract][Full Text] [Related]
6. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
[TBL] [Abstract][Full Text] [Related]
8. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
[TBL] [Abstract][Full Text] [Related]
9. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB; Mackin S; Errico JM; Chong Z; Madden EA; Whitener B; Guarino B; Schmid MA; Rosenthal K; Ren K; Dang HV; Snell G; Jung A; Droit L; Handley SA; Halfmann PJ; Kawaoka Y; Crowe JE; Fremont DH; Virgin HW; Loo YM; Esser MT; Purcell LA; Corti D; Diamond MS
Nat Commun; 2022 Jul; 13(1):3824. PubMed ID: 35780162
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate.
Touret F; Baronti C; Bouzidi HS; de Lamballerie X
Sci Rep; 2022 Mar; 12(1):4683. PubMed ID: 35304531
[TBL] [Abstract][Full Text] [Related]
11. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
[TBL] [Abstract][Full Text] [Related]
13. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.
Tada T; Zhou H; Dcosta BM; Samanovic MI; Chivukula V; Herati RS; Hubbard SR; Mulligan MJ; Landau NR
EBioMedicine; 2022 Apr; 78():103944. PubMed ID: 35465948
[TBL] [Abstract][Full Text] [Related]
14. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
Shah M; Woo HG
Front Immunol; 2021; 12():830527. PubMed ID: 35140714
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
[TBL] [Abstract][Full Text] [Related]
16. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5.
Touret F; Baronti C; Pastorino B; Villarroel PMS; Ninove L; Nougairède A; de Lamballerie X
Sci Rep; 2022 Jul; 12(1):12609. PubMed ID: 35871089
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
Tuccori M; Ferraro S; Convertino I; Cappello E; Valdiserra G; Blandizzi C; Maggi F; Focosi D
MAbs; 2020; 12(1):1854149. PubMed ID: 33319649
[TBL] [Abstract][Full Text] [Related]
19. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
20. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.
Chen J; Wang R; Gilby NB; Wei GW
J Chem Inf Model; 2022 Jan; 62(2):412-422. PubMed ID: 34989238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
